Breast Cancer Monoclonal Antibodies Market key drive and Regional Share, Trends, Competitor Analysis to 2025

This report studies the global Breast Cancer Monoclonal Antibodies market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Breast Cancer Monoclonal Antibodies market by companies, region, type and end-use industry.

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.

The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.

The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.

Request Sample Report Copy@ https://www.qyresearch.com/sample-form/form/559371/global-breast-cancer-monoclonal-antibodies-market

In 2017, the global Breast Cancer Monoclonal Antibodies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

This report focuses on the global top players, covered

Amgen

Roche

Mylan

Array BioPharma

Biocad

Boehringer Ingelheim

Bristol-Myers Squibb

Celldex Therapeutics

Celltrion

Daiichi Sankyo

GlaxoSmithKline

Immunomedics

MacroGenics

Merck

Novartis

Oncothyreon

Pfizer

Puma Biotechnology

Seattle Genetics

Sun Pharmaceutical Industries

Synta Pharmaceuticals

Teva Pharmaceuticals

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Market segment by Type, the product can be split into

Naked MAbs

Conjugated MAbs

Market segment by Application, split into

Hospitals

Retail Pharmacies

Others

Get Amazing Discount on Market Research Report@ https://www.qyresearch.com/request-discount/form/559371/global-breast-cancer-monoclonal-antibodies-market

About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact US
QY Research, INC.
17890 Castleton, Suite 218,
Los Angeles, CA - 91748
USA: +1 6262 952 442
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
Emails – sales@qyresearch.com
Web – www.qyresearch.com
Expert News: https://www.qyresearch.com/expert/list

This release was published on openPR.